Although similar changes in the SUV max and the volume of inflammation suggested greater changes in the evolocumab group, these did not reach statistical significance.
← all excerpts
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial.
1
—
—